Intended for licensed healthcare professionals located in Switzerland.
Stay up to date with the latest news on PEMAZYRE®▼ (pemigatinib).
Please complete the form below to receive relevant information from Incyte, such as further information on PEMAZYRE and treatment of cholangiocarcinoma (CCA).